SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia

Not checked yet

• Fifteen diagnostic samples include twelve initial network-analysis cases, three longitudinal MRD cases and only one primary viability case. Technical triplicates and dependent cell subsets are not independent patients. Timing, compartments and treatment conditions vary.
• Basal STAT5, aggregate ruxolitinib response and one subset comparison did not reach significance. A low-CRLF2 negative model showed no tested combination effect. Too few cells prevented one MRD network analysis. Pairwise associations are not causal pathway or lineage proof.
• Supplement Figure5’s caption reverses the patient labels printed on its panels. Main captions/methods printp<.5 while the stated alpha is.05; supplement wording differs. WBC units/values, a missing percent sign and an MRD denominator ambiguity remain literal and unresolved.
• Nolan supervised research and disclosed paid Fluidigm consulting. A mandatory additive metadata erratum fixes an empty author array from a parser error; all17 native names were verified and frozen source bytes preserved. It adds no body-reading credit.
• Original main layout, some fine figure glyphs, native version identifier, unshown results, raw FCS, experimental records and code remain unavailable. No code was executed or private patient records collected. Published aggregate findings do not establish clinical efficacy, safety or UAP validation.